REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

Key Takeaways Regeneron to post Q3 results on Oct. 28, with earnings forecast at $9.54 per share on $3.60B revenues.Dupixent profits likely rose on 26.2% higher sales across multiple approved disease indications.Strong demand for Eylea HD could offset declines in Eylea. Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. (REGN) reports third-quarter 2025 results on Oct. 28, 2025.The Zacks Consensus Estimate for revenues is pegged ...